Cold Chain Technologies (CCT) has launched its first major innovation since acquiring Tower Cold Chain in 2024: a reusable, temperature-controlled pallet shipper tailored for the life sciences industry. The 1600L capacity unit, called the CCT Tower Elite, was officially introduced at
“We’ve combined these two solid legacies into a new, agile CDMO with a unique focus on high-value small and medium-scale production,” says Bruce Vielle, CEO of the newly formed Meribel Pharma Solutions. Bruce Vielle, an experienced industrial business leader with
Lonza, a global development and manufacturing partner for the pharmaceutical and biotech sectors, has joined CMAC to strengthen its service offering in particle technologies and drug product development. CMAC, based at the University of Strathclyde in Scotland, is a medicines
Curium, a global company in nuclear medicine, has completed the acquisition of Nucleis, a GMP manufacturer and distributor of PET radiopharmaceutical drugs based in Belgium. The transaction supports Curium’s strategy to strengthen its position in the PET imaging market and
Cellistic, a specialist in induced pluripotent stem cell (iPSC)-based therapies, has launched the Echo-NK platform to support the large-scale manufacture of allogeneic Natural Killer (NK) cell treatments. The new platform builds on the company’s Echo Platform introduced in 2023. The
Novartis, a global pharmaceutical company, has announced a $23 billion investment over five years to expand its manufacturing and research presence across the United States. The company aims to ensure all key Novartis medicines for US patients are produced domestically.
“Trust is what your customers need most. They take a great risk when they sign up with you to make their product. They need access within your organization to feel confident you’ll get things done the way they want.” –
Cellares, an Integrated Development and Manufacturing Organization (IDMO), has entered into a strategic collaboration with the University of Wisconsin School of Medicine and Public Health. The aim is to automate the manufacturing of a CRISPR-edited GD2 CAR-T investigational therapy. The
Granules India has announced the successful completion of its acquisition of Senn Chemicals AG, a Switzerland-based Contract Development and Manufacturing Organization (CDMO) with expertise in peptide development and manufacturing. The deal was executed through Granules’ wholly owned Indian subsidiary, Granules Peptides. The
SCHOTT Pharma has officially opened its new glass ampoule production facility in Jagodina, Serbia, marking a key expansion in its global manufacturing network. The inauguration took place on 10 April 2025, following the groundbreaking in December 2023. The company’s investment, described
Help us find the most innovative and trusted suppliers in Pharma and Biotech.
